Unicycive Therapeutics unveils new kidney disease treatment pipeline in latest corporate presentation

Unicycive Therapeutics Inc. has released a corporate presentation detailing its current pipeline and development strategy in the field of kidney disease. The company’s lead asset, oxylanthanum carbonate (OLC), is being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Unicycive plans to resubmit the New Drug Application (NDA) for OLC by the end of the year, following discussions with the FDA regarding the resolution of a previously identified manufacturing vendor compliance issue. If approved, OLC is expected to offer a lower pill burden compared to existing therapies, addressing a significant unmet need according to surveyed nephrologists. The company is also advancing UN-494, which is in development for the treatment of acute kidney injury and chronic kidney disease. Unicycive reports a cash runway extending into 2027 to support its ongoing clinical and commercial activities. You can access the full presentation through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Unicycive Therapeutics Inc. published the original content used to generate this news brief on December 02, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here